A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT ID: NCT05400369

Last Updated: 2025-01-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 140 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-10
• Study Completion Date: 2024-09-25

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation.

Acute exacerbation, especially frequent exacerbation, is associated with an increased risk of death in COPD patients. The most common causes of acute attacks are viral and bacterial infections.

This study will assess the efficacy and safety of sitafloxacin, a quinolone antibacterial drug, in participants with AECOPD.

Detailed Description

Clinical evidence suggests that AECOPD may be an important factor in the cause of death in patients with COPD. AECOPD typically presents with increased dyspnea, cough, and sputum volume, or purulent changes in sputum. The most common factors of AECOPD are viral and bacterial infections. Anti-infection agents have shown to be effective in patients with infectious AECOPD.

This study will assess the anti-bacterial drug sitafloxacin in participants with AECOPD. Clinical efficacy is the primary objective of the study. Microbiological validity, symptom relief, magnitude of change in symptom score and inflammatory biomarker, and recurrence rate and safety will also be assessed.

Conditions

COPD Exacerbation Acute

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sitafloxacin

Adult participants who will be randomized to receive 100 mg sitafloxacin (2 tablets) orally once a day.

Group Type: EXPERIMENTAL

Sitafloxacin

Intervention Type: DRUG

Oral administration, 50 mg tablets

Moxifloxacin

Adult participants who will be randomized to receive 400 mg moxifloxacin (1 tablet) orally every 24 hours.

Group Type: ACTIVE_COMPARATOR

Moxifloxacin Hydrochloride

Intervention Type: DRUG

Oral administration, 400 mg tablets

Interventions

Sitafloxacin

Oral administration, 50 mg tablets

Intervention Type: DRUG

Moxifloxacin Hydrochloride

Oral administration, 400 mg tablets

Intervention Type: DRUG

Other Intervention Names

Gracevit; Avelox

Eligibility Criteria

Inclusion Criteria

• Age ≥ 40;
• History of moderate to very severe COPD with a post-bronchodilator Forced Expiratory Volume in One Second/Forced Vital Capacity (FEV1/FVC) < 70% and a post-bronchodilator Forced Expiratory Volume in One Second (FEV1) < 80% of predicted normal value within one year prior to enrollment;
• History of one or more acute exacerbations within one year prior to enrollment;
• At least 6 weeks of stable disease prior to enrollment;
• The acute exacerbation is classified as Anthonisen I (with 3 main symptoms of worsening dyspnea, increased sputum volume and sputum purulence) or II (with sputum purulence and another main symptom);
• Participants can be treated on an outpatient basis after clinical assessment.

Exclusion Criteria

• Anthonisen III acute exacerbation (Have two major symptoms of worsening dyspnea and increased sputum volume or one of the two major symptoms)
• Hospitalization or intensive care unit (ICU) treatment is required
• Sputum culture within the previous year indicated the presence of pathogenic microorganisms resistant to quinolones
• Quinolone allergy
• History of QTc prolongation, or need for medications to treat QTc prolongation (e.g., Class Ia or Class III antiarrhythmics);
• Definite pulmonary disease other than COPD (asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism, pulmonary fibrosis, lung cancer)
• History of severe cardiovascular disease (e.g., congestive heart failure, clinically significant coronary heart disease, stroke, myocardial infarction and/or stroke within 6 months, clinically significant arrhythmia, previous history of aortic aneurysm or aortic dissection, positive family history, or risk factors (e.g., Marfan syndrome), poorly controlled hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg on 2 or more consecutive measurements)
• Severe systemic diseases, such as severe dizziness, headache and other nervous system diseases
• Malignant tumor
• Concomitant or history of tendon disease or myasthenia gravis or Parkinson's disease
• Abnormal liver function, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) level > 3 times the upper limit of normal, and/or total bilirubin level >2 times the upper limit of normal
• With moderate or severe decline of renal function, endogenous creatinine clearance rate (Ccr) < 50ml/min
• History of seizure, or psychiatric condition that could affect compliance with the protocol, or risk for suicide, or history of alcohol or illicit drug abuse
• Immunocompromised participants using glucocorticoids (total dose equivalent to prednisone 20 mg daily for more than 2 weeks) or immunosuppressive agents or HIV infected participants
• Gastrointestinal disorders that may affect drug absorption (e.g., active Crohn's disease, active ulcerative colitis)
• Pregnant or lactating women or women of childbearing potential who are planning to become pregnant
• Participation in other clinical trials within 3 months prior to screening
• Used antibiotics (including systemic and inhalation) 30 days before enrollment
• Serum potassium < 3.5mmol/L at screening, or repeated hypokalemia that was difficult to correct in the past
• Other reasons that the investigator considered inappropriate to participate in the study.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daiichi Sankyo

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Global Clinical Director

Role: STUDY_DIRECTOR

Daiichi Sankyo

Locations

Peking University Shougang Hospital

Beijing, , China

The Third Xiangya Hospital of Central South University

Changsha, , China

The Sixth People's Hospital of Chengdu

Chengdu, , China

West China Hospital Sichuan University

Chengdu, , China

The First Affiliated Hospital of Dalian Medical University

Dalian, , China

Fuyang People's Hospital

Fuyang, , China

Nanfang Hospital Southern Medical University

Guangzhou, , China

Qilu Hospital of Shandong University

Jinan, , China

Gaozhou People's Hospital

Maoming, , China

Huadong Hospital Affiliated To Fudan University

Shanghai, , China

Shenzhen People's Hospital

Shenzhen, , China

Tianjin Medical University General Hospital

Tianjin, , China

The Sixth Hospital of Wuhan

Wuhan, , China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, , China

The Affiliated Hospital of Xuzhou Medical University

Xuzhou, , China

The First Affiliated Hospital of Hebei North University

Zhangjiakou, , China

Affiliated Hospital of Guangdong Medical University

Zhanjiang, , China

Henan Provincial People's Hospital

Zhengzhou, , China

Countries

China

Other Identifiers

DSCN-GRV AECOPD-CSIS-001

Identifier Type: -

Identifier Source: org_study_id